:::

詳目顯示

回上一頁
題名:於同類藥品中選最符合成本效益之藥品來治療取代:以Statins為例
書刊名:臺灣臨床藥學雜誌
作者:溫婉婷譚延輝羅柏青李玟瑾
作者(外文):Wen, Wan-tingTarn, Yen-hueiLo, Po-chingLi, Wen-chin
出版日期:2011
卷期:19:1
頁次:頁11-33
主題關鍵詞:治療取代血脂異常成本效果分析健保資料庫Therapeutic interchangeDyslipidemiaStatinCost-effectiveness analysisClaim database analysis
原始連結:連回原系統網址new window
相關次數:
  • 被引用次數被引用次數:期刊(0) 博士論文(0) 專書(0) 專書論文(0)
  • 排除自我引用排除自我引用:0
  • 共同引用共同引用:0
  • 點閱點閱:28
期刊論文
1.Wall, D. S.、Abel, S. R.(1996)。Therapeutic-interchange algorithm for multiple drug classes。AJHP,53,1295-1296。  new window
2.National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)(2002)。Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report。Circulation,106,3143-3421。  new window
3.Olsson, A. Q.、Istad, H.、Luurila, O.、Ose, L.、Stender, S.、Tuomilehto, J.(2002)。Effects of rosuvastatin and atorvastatin conpared over 52 weeks of treatment in patients with hypercholesterolemia。Am Heart J,144,1044-1051。  new window
4.紀櫻珍、林裕能、王美玉、吳振龍(20050100)。臺北市立醫院自主管理之初步評估。北市醫學雜誌,2(1),61-70。  延伸查詢new window
5.吳帆、楊耀山(20031200)。醫院自主管理指標資訊系統建構--以中部某區域醫院為例。醫務管理期刊,4(4),59-76。new window  延伸查詢new window
6.American College of Clinical Pharmacy(1993)。ACCP position statement: guidelines for therapeutic interchange。Pharmacotherapy,13,252-256。  new window
7.Gray, T.、Bertch, K.、Galt, K.、Gonyeau, M.、Karpiuk, E.、Oyen, L.(2005)。American College of Clinical Pharmacy. ACCP position statement: guidelines for therapeutic interchange-2004。Pharmacotherapy,25,1666-1680。  new window
8.Brown, W. V.、Bays, H. E.、Hassman, D. R.、McKenney, J.、Chitra, R.、Hutchinson H.(2002)。Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial。Am Heart J,144,1036-1043。  new window
9.Shepherd, J.、Vidt, D. G.、Miller, E.、Harris, S.、Blasetto, J.(2007)。Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program。Cardiology,107,433-443。  new window
10.Pedersen, T. R.(1994)。Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)。Lancet,344,1383-1389。  new window
11.Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group(1998)。Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels。N Engl J Med,339(19),1349-1357。  new window
12.Murray, C. J.、Evans, D. B.、Acharya, A.、Baltussen, R. M.(2000)。Development of WHO guidelines on generalized cost-effectiveness analysis。Health Economics,9(3),235-251。  new window
13.Benner, J. S.、Smith, T. W.、Klingman, D.、Tierce, J. C.、Mullins, C. D.、Pethick, N.(2005)。Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective。Value Health,8,618-628。  new window
14.Karlsson, G.、Johannesson, M.(1996)。The decision rules of cost-effectiveness analysis。Pharmacoeconomics,9,113-120。  new window
15.Sendi, P.、Al, M. J.(2003)。Revisiting the decision rule of cost-effectiveness analysis under certainty and uncertainty。Soc Sci Med,57,969-974。  new window
16.Stamier, J.、Wentworth, D.、Neaton, J. D.(1986)。Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356, 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).。JAMA,256(20),2823-2828。  new window
17.Law, M. R.、Wald, N. J.、Thompson, S. G.(1994)。By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?。BMJ,308,367-372。  new window
18.Rasnake, C. M.、Trumbo, P. R.、Heinonen, T. M.(2008)。Surrogate endpoints and emerging surrogate endpoints for risk reduction of cardiovascular disease。Nutr Rev,66,76-81。  new window
19.Costa-Scharplatz, M.、Ramanathan, K.、Frial, T.、Beamer, B.、Gandhi, S.(2008)。Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective。Clin Ther,30,1345-1357。  new window
20.Ohsfeldt, R. L.、Gandhi, S. K.、Fox, K. M.、McKenney, J. M.(2008)。Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications。Value Health,11,1061-1069。  new window
21.Pinto, C. Q.、Carrageta, M. O.、Miguel, L. S.(2008)。Cost-effectiveness of rosuvastatin in the prevention of ischemic heart disease in Portugal。Value Health,11,154-159。  new window
會議論文
1.謝幸燕、呂慶祥、范保羅(2006)。總額預算制與醫院的藥品處方管理策略。南台灣健康產業研討會。屏東。  延伸查詢new window
學位論文
1.李玟瑾(2008)。療取代:評估降血脂類藥品statins之治療相等性以及選擇適當的statin藥品替代(碩士論文)。國防醫學院。  延伸查詢new window
圖書
1.Helfand, M.、Carson, S.、Kelley, C.(2006)。Drug class review on HMG-CoA reductase inhibitors (Statins)。Oregon Evidence-based Practice Center, Oregon Health & Science University。  new window
2.Tan-Torres Edejer, T.、Baltussen, R.、Adam, T.、Hutubessy, R.、Acharya, A.、Evans, D. B.(2003)。Making choices in health: WHO guide to cost-effectiveness analysis。Geneva:World Health Organization。  new window
3.Institute for Quality and Efficiency in Health Care(2008)。Methods for assessment of the relation of benefits to costs in the German statutory health care system。Cologne:Institute for Quality and Efficiency in Health Care。  new window
4.Lacy, C. F.、Armstrong, L. L.、Goldman, M. P.、Lance, L. L.(2009)。Drug information handbook: a comprehensive resource for all clinicians and healthcare professionals。Hudson:Lexi-Comp。  new window
其他
1.(2009)。DRGs支付制度,台北:中央健康保險局。,http://www.nhi_gov.tw/ webdata/webdata.asp?menu=l &menu_id=:2 6&webdata_id=937, 2009/04/09。  new window
2.(2008),台北:台灣藥物經濟曁效果研究學會。,http://www.taspor.org/ wp-content/uploads/2007/12/2006pe_guideli nes.pdf, 2008/10/17。  new window
 
 
 
 
第一頁 上一頁 下一頁 最後一頁 top
:::
無相關博士論文
 
無相關書籍
 
無相關著作
 
無相關點閱
 
QR Code
QRCODE